Brain-penetrating angiotensin-converting enzyme inhibitors and cognitive change in patients with dementia due to alzheimer's disease

Journal of Alzheimer's Disease

Volumn 42, Issue , 2014, Pages S321-S324

  De Oliveira, Fabricio Ferreira ^a   Bertolucci, Paulo Henrique Ferreira ^a   Chen, Elizabeth Suchi ^a   Smith, Marilia Cardoso ^a  

^a FEDERAL UNIVERSITY OF SÃO PAULO   (Brazil)

Author keywords

Alzheimer's disease; dementia; drug therapy; neurodegenerative diseases; neuropsychiatry; pharmacogenetics

Indexed keywords

ADIPONECTIN; CAPTOPRIL; ENALAPRIL; MEMBRANE METALLOENDOPEPTIDASE; PERINDOPRIL; DIPEPTIDYL CARBOXYPEPTIDASE; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR;

ACETYLCHOLINE RELEASE; ADULT; AGED; ALZHEIMER DISEASE; BLOOD PRESSURE REGULATION; CAUDATE NUCLEUS; CLINICAL DEMENTIA RATING; COGNITION; CONFERENCE PAPER; CONTROLLED STUDY; DISEASE ASSOCIATION; DISEASE COURSE; FEMALE; FRONTAL CORTEX; GENE FREQUENCY; GENOTYPE; GLUCOSE HOMEOSTASIS; HAPLOTYPE; HIPPOCAMPUS; HUMAN; HYPERTENSION; INCIDENCE; INDEL MUTATION; INSULIN SENSITIVITY; MAJOR CLINICAL STUDY; MALE; MENTAL DETERIORATION; MILD COGNITIVE IMPAIRMENT; MINI MENTAL STATE EXAMINATION; MORTALITY; ONSET AGE; PATHOGENESIS; PROMOTER REGION; REAL TIME POLYMERASE CHAIN REACTION; RENIN ANGIOTENSIN ALDOSTERONE SYSTEM; RISK FACTOR; SINGLE NUCLEOTIDE POLYMORPHISM; TRANSCRIPTION INITIATION SITE; TREATMENT OUTCOME; COGNITION DISORDERS; COMPLICATION; GENETICS; MENTAL HEALTH; MIDDLE AGED; NEUROPSYCHOLOGICAL TEST; PHARMACOGENETICS; VERY ELDERLY;

AGED; AGED, 80 AND OVER; ALZHEIMER DISEASE; ANGIOTENSIN-CONVERTING ENZYME INHIBITORS; COGNITION DISORDERS; FEMALE; HUMANS; MALE; MENTAL STATUS SCHEDULE; MIDDLE AGED; NEUROPSYCHOLOGICAL TESTS; PEPTIDYL-DIPEPTIDASE A; PHARMACOGENETICS; POLYMORPHISM, SINGLE NUCLEOTIDE;

EID: 84919867028     PISSN: 13872877     EISSN: 18758908     Source Type: Journal    
DOI: 10.3233/JAD-132189     Document Type: Conference Paper

References (17)

1. de Oliveira FF, Bertolucci PH, Chen ES, Smith Mde A (2014) Pharmacological modulation of cognitive and behavioral symptoms in patients with dementia due to Alzheimer's disease. J Neurol Sci 336, 103-108.
2. Solfrizzi V, Panza F, Colacicco AM, D'Introno A, Capurso C, Torres F, Grigoletto F, Maggi S, Del Parigi A, Reiman EM, Caselli RJ, Scafato E, Farchi G, Capurso A (2004) Vascular risk factors, incidence of MCI, and rates of progression of dementia. Neurology 63, 1882-1891.
3. Kehoe PG, Wilcock GK (2007) Is inhibition of the renin-angiotensin system a new treatment option for Alzheimer's disease? Lancet Neurol 6, 373-378.
4. Furiya Y, Ryo M, Kawahara M, Kiriyama T, Morikawa M, Ueno S (2013) Renin-angiotensin system blockers affect cognitive decline and serum adipocytokines in Alzheimer's disease. Alzheimers Dement 9, 512-518.
5. Ohrui T, Tomita N, Sato-Nakagawa T, Matsui T, Maruyama M, Niwa K, Arai H, Sasaki H (2004) Effects of brainpenetratingACEinhibitors on Alzheimer disease progression. Neurology 63, 1324-1325.
6. Hemming ML, Selkoe DJ (2005) Amyloid β-protein is degraded by cellular angiotensin-converting enzyme (ACE) and elevated by an ACE inhibitor. J Biol Chem 280, 37644-37650.
7. Kehoe PG, Davies NM, Martin RM, Ben-Shlomo Y (2013) Associations of angiotensin targeting antihypertensive drugs with mortality and hospitalization in primary care patients with dementia. J Alzheimers Dis 33, 999-1008.
8. Kehoe PG, Katzov H, Andreasen N, Gatz M, Wilcock GK, Cairns NJ, Palmgren J, de Faire U, Brookes AJ, Pedersen NL, Blennow K, Prince JA (2004) Common variants of ACE contribute to variable age-at-onset of Alzheimer's disease. Hum Genet 114, 478-483.
9. Chung C-M, Wang R-Y, Fann CSJ, Chen J-W, Jong Y-S, Jou Y-S, Yang H-C, Kang C-S, Chen C-C, Chang H-C, Pan WH(2013) Fine-mapping angiotensin-converting enzyme gene: Separate QTLs identified for hypertension and for ACE activity. PLoS ONE 8, e56119.
10. Bertram L, Tanzi RE (2008) Thirty years of Alzheimer's disease genetics: The implications of systematic meta-analyses. Nature Rev Neurosci 9, 768-778.
11. McKhann GM, Knopman DS, Chertkow H, Hyman BT, Jack CR Jr, Kawas CH, Klunk WE, Koroshetz WJ, Manly JJ, Mayeux R, Mohs RC, Morris JC, Rossor MN, Scheltens P, Carillo MC, Thies B, Weintraub S, Phelps CH (2011) The diagnosis of dementia due to Alzheimer's disease: Recommendations from the National Institute on Aging and the Alzheimer's Association workgroup. Alzheimers Dement 7, 263-269.
12. Morris JC (1993) The Clinical Dementia Rating (CDR): Current version and scoring rules. Neurology 43, 2412-2414.
13. Folstein MF, Folstein S, McHugh PR (1975) Mini-Mental State: A practical method for grading the cognitive state of patients for the clinician. J Psychiatry Res 12, 189-198.
14. BertolucciPHF, BruckiSMD,Campacci SR, JulianoY(1994) The Mini-Mental State Examination in an outpatient population: Influence of literacy. Arq Neuropsiquiatr 52, 1-7.
15. Harrell LE, Marson D, Chatterjee A, Parrish JA (2000) The Severe Mini-Mental State Examination: A new neuropsychologic instrument for the bedside assessment of severely impaired patients with Alzheimer disease. Alzheimer Dis Assoc Disord 14, 168-175.
16. Leszek J, Sochocka M, G?asiorowski K (2012) Vascular factors and epigenetic modifications in the pathogenesis of Alzheimer's disease. J Neurol Sci 323, 25-32.
17. Bomboi G, Castello L, Cosentino F, Giubilei F, Orzi F, Volpe M (2010) Alzheimer's disease and endothelial dysfunction. Neurol Sci 31, 1-8.